A panel of murine monoclonal antibodies (MAbs) to the human immunodeficiency virus type 1 transactivator tat protein were characterized. The anti-tat MAbs were mapped to the different domains of the tat protein by Western blot (immunoblot) and Pepscan analyses. One-half of the MAbs tested mapped to the amino-terminal proline-rich region, and one-third of the MAbs tested mapped to the lysine-arginine-rich region of tat. The individual MAbs were tested for inhibition of tat-mediated trans activation, using a cell-based in vitro assay system. MAbs which mapped to the amino-terminal region of the tat protein demonstrated the highest degree of inhibition, whereas MAbs reactive to other portions of the molecule exhibited a less pronounced effect on tat function.
The etiological agent of the acquired immunodeficiency syndrome is believed to be a retrovirus, designated human immunodeficiency virus type 1 (HIV-1) (4, 13) . HIV-1 exhibits the same gag-pol-env genomic organization as all retroviruses, and it also encodes a handful of additional proteins, most of which have been shown to play a regulatory function (7, 27) . One of these regulatory proteins, termed tat or trans activator, is absolutely required for viral gene expression and replication (8, 11) and is thus a potential target for therapeutic intervention in the treatment of HIV-1 infection. This therapeutic approach is not trivial, since the precise mechanism by which tat regulates HIV-1 gene expression and viral growth is still unknown. trans activation by transcriptional and posttranscriptional mechanisms have been proposed (6) . Site-directed mutagenesis of the trans-activation response element located within the HIV-1 long terminal repeat (LTR) has been used to define critical sequences necessary for tat-induced viral gene expression (10, 15) . A similar approach has been utilized to identify functional domains of the tat protein apparently responsible for trans activation and subcellular localization (14, 25) . In addition, a number of cis-acting regulatory elements located within the HIV-1 LTR mediate responses to a wide range of constitutive and inducible cellular transcription factors which may act synergistically with tat to further amplify viral gene expression (7) . In an effort to gain additional information on the structure and function of tat, we developed murine monoclonal antibodies (MAbs) against a bacterially produced tat protein. We used these anti-tat MAbs to identify immunodominant epitopes on tat and to try to define domains of tat involved in trans activation of the HIV-1 LTR.
BALB/c mice were immunized subcutaneously with 25 ,ug of full-length tat protein purified from induced pOTS-TATIII (1; T. Smith, S. Franklin, and C. Debouck, unpublished data) in Freund complete adjuvant and then given two boosts in incomplete Freund adjuvant 4 and 6 weeks later. Spleens from immunized mice were removed, and hybridomas were * Corresponding author.
produced by using standard techniques (19 The expression vectors pOTS-TATIII-DP, pOTS-TATIII-DC, and pOTS-TATIII-DLA encode mutant tat proteins with deletions that approximate these regions (Table 1 ).
In order to more precisely define the epitopes recognized by each MAb on the tat protein, the reactivity of all MAbs to overlapping nonapeptides (1 to 9, 2 to 10, etc.) spanning the entire tat sequence was determined by Pepscan essentially as described elsewhere (16) were plated in microtiter wells, and culture supernatants were removed 90 min later and assayed for levels of tPA expression. Results of a typical experiment are presented in which mapped to the basic domain of tat had a moderate inhibitory effect on trans activation, whereas MAb 4 (moderate inhibition level), and 10 (no inhibition) were measured and determined to be equivalent 90 min postincubation (data not shown). To control for MAb toxicity, these same MAbs (4, 7, and 10) were assayed for tPA inhibition in the tat nonresponsive TNT2.1 cell line and found to possess no significant inhibitory activity (data not shown).
VOL. 64, 1990 activation. The three MAbs which demonstrated the highest degree of tat inhibition recognize the same linear epitope, VDPRLEPWK, in the amino-terminal proline-rich region of tat, suggesting that this region is important for tat function. These results are in agreement with our observations that a tat deletion mutant missing the proline-rich region fails to trans activate the HIV-1 LTR (data not shown). These data are also concordant with published results from several laboratories (14, 21, 25) , including recent data which demonstrated that substitution of the acidic residues within the amino-terminal portion of the molecule had a profound effect on tat function (24) . In contrast, a recent report describing the use of tat deletion peptides (17) has suggested that the first 36 amino acids of tat are unnecessary for trans activation, but these conflictual results have not been resolved.
Finally, it is interesting that the inhibition of tat activity seen in these experiments was partial and temporary. The 
